091990 — Celltrion Healthcare Co Share News
0.000.00%
HealthcareAdventurousLarge Cap
- KR₩12tn
- KR₩12tn
- KR₩2tn
Celltrion signs COVID-19 antibody therapy supply deals with Europe
Brief: Celltrion’S Monoclonal Antibody Treatment Regdanvimab, Approved By European Commission For Treatment Of Covid-19
Brief: EC Formally Authorises COVID-19 Drugs From Regeneron-Roche, Celltrion
EU regulator endorses COVID-19 drugs from Regeneron-Roche, Celltrion (updated)
EU regulator backs approval of COVID-19 drugs from Regeneron-Roche, Celltrion
Brief: EMA's CHMP Recommends Authorising Ronapreve And Regkirona For COVID-19
Amid spike in cases, EU to shortly approve first COVID antibody drugs - sources
Amid spike in cases, EU to shortly approve first COVID antibody drugs - sources
Brief: EMA Gets Application For Marketing Authorisation For Regkirona For Treating COVID-19
EU signs joint procurement deal for Eli Lilly COVID-19 treatment
Brief: Celltrion Healthcare Says Co And 180 Life Sciences Enter Into Memorandum Of Understanding
South Korea approves Celltrion's COVID-19 treatment for use
Brief: Celltrion Healthcare Announces Acceptance And Priority Review By Health Canada Of New Drug Submission For Its Monoclonal Antibody Treatment For Covid-19, Regdanvimab (Ct-P59)
Brief: Celltrion's Regdanvimab Shows Strong Neutralising Activity Against Delta Variant In Animal Test
Media: Celltrion expects COVID variants to fuel global treatments growth - FT
EU picks antibody treatments, arthritis drug as preferred COVID-19 therapies
S.Korea Celltrion's candidate COVID-19 drug gets approval for special-case use
S.Korea's Celltrion: Surges as co completes patient recruitment for COVID-19 drug trial
S.Korea's COVID-19 test kit makers, vaccine makers fall after Pfizer vaccine report